HomeCompareLVTX vs CHD

LVTX vs CHD: Dividend Comparison 2026

LVTX yields 114.94% · CHD yields 1.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LVTX wins by $7.02M in total portfolio value
10 years
LVTX
LVTX
● Live price
114.94%
Share price
$1.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.05M
Annual income
$2,599,161.52
Full LVTX calculator →
CHD
CHD
● Live price
1.28%
Share price
$93.32
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,302.64
Full CHD calculator →

Portfolio growth — LVTX vs CHD

📍 LVTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLVTXCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LVTX + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LVTX pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LVTX
Annual income on $10K today (after 15% tax)
$9,770.11/yr
After 10yr DRIP, annual income (after tax)
$2,209,287.29/yr
CHD
Annual income on $10K today (after 15% tax)
$108.62/yr
After 10yr DRIP, annual income (after tax)
$1,107.24/yr
At 15% tax rate, LVTX beats the other by $2,208,180.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LVTX + CHD for your $10,000?

LVTX: 50%CHD: 50%
100% CHD50/50100% LVTX
Portfolio after 10yr
$3.54M
Annual income
$1,300,232.08/yr
Blended yield
36.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

LVTX
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Price Target
$3.75
+115.5% upside vs current
Range: $1.50 — $6.00
Altman Z
-4.7
Piotroski
1/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+5.4% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LVTX buys
0
CHD buys
0
No recent congressional trades found for LVTX or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLVTXCHD
Forward yield114.94%1.28%
Annual dividend / share$2.00$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$7.05M$26.4K
Annual income after 10y$2,599,161.52$1,302.64
Total dividends collected$6.38M$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$3.75$98.40

Year-by-year: LVTX vs CHD ($10,000, DRIP)

YearLVTX PortfolioLVTX Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$22,194$11,494.25$10,857$157.30+$11.3KLVTX
2$47,590$23,841.72$11,814$196.49+$35.8KLVTX
3$98,699$47,777.67$12,887$245.97+$85.8KLVTX
4$198,214$92,606.18$14,097$308.68+$184.1KLVTX
5$385,900$173,811.71$15,473$388.49+$370.4KLVTX
6$729,168$316,254.64$17,046$490.55+$712.1KLVTX
7$1,338,687$558,477.43$18,861$621.76+$1.32MLVTX
8$2,390,633$958,237.97$20,973$791.47+$2.37MLVTX
9$4,157,254$1,599,276.16$23,454$1,012.51+$4.13MLVTX
10$7,047,423$2,599,161.52$26,398$1,302.64+$7.02MLVTX

LVTX vs CHD: Complete Analysis 2026

LVTXStock

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Full LVTX Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this LVTX vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LVTX vs SCHDLVTX vs JEPILVTX vs OLVTX vs KOLVTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.